Non Viral Delivery Methods 2019

Progressing Non-Viral Gene Therapy Approaches in GI Tract & Bladder Diseases


Published: 4 February 2019
Anthony Cheung

Anthony Cheung is the co-founder and Chief Technology Officer of enGene, a private biotechnology company headquartered in Montreal, Canada. He served as the Chief Executive Officer of enGene from 2012 to 2018. Dr Cheung is a co-inventor of enGene’s non-viral gene delivery platform for mucosal tissues and its Gene PillTM technology. During his tenure as the CEO, he raised significant financing to grow the company through venture-backed equity financing and government funding. He also successfully completed two partnership transactions with Johnson & Johnson and Takeda. enGene was awarded by BIOTECanada in 2017 as the Biotech Company of the Year. Dr Cheung was recognized in 2016 by Biotechnology Focus, a Canadian life science-focused trade publication, as one of the Top 5 Biotech CEO in Canada and selected as the EY Entrepreneur of the Year Finalist in 2017. Dr Cheung received his doctorate degree in Physiology from the Tulane University School of Medicine in New Orleans. Dr Cheung has co-authored numerous book chapters, review articles and peer-reviewed journals on the topics of diabetes, gene therapy and autoimmune diseases. His research has been published in many prestigious scientific journals, including Science and Proceedings of the National Academy of Science. He has been invited to speak at many international scientific and biotechnology conferences – BIO, American Society for Gene & Cell Therapy, Diabetes Technology Meeting, Children with Diabetes – on topics related to gene therapy, diabetes and bio-entrepreneurism. He also serves as Board Member and Advisor for several biotechnology companies and professional organizations including Bio-Industry Liaison Committee of the American Society for Gene and Cell Therapy and Student Biotechnology Network of BC.